Brief: Avenue Therapeutics Says First Patient Dosed In Phase 1B/2A Trial Of AJ201
27/07/2023 15:06
July 27 (Reuters) - Avenue Therapeutics Inc ATXI.O :
* AVENUE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE
1B/2A
CLINICAL TRIAL OF AJ201 FOR THE TREATMENT OF SPINAL AND BULBAR
MUSCULAR ATROPHY (KENNEDY'S DISEASE)
* AVENUE THERAPEUTICS INC - ENROLLMENT IN TRIAL IS EXPECTED
TO BE
COMPLETE BY END OF 2023 OR EARLY 2024 WITH POTENTIAL TOPLINE
DATA IN 2024
Source text for Eikon: ID:nGNX7yycjT
Further company coverage: ATXI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi